Status quo of domestically approved small molecule drugs against novel coronavirus and their application
10.3760/cma.j.issn.1674-2397.2023.05.010
- VernacularTitle:近期国内批准抗新型冠状病毒小分子药物研究概况与评价
- Author:
Jifang SHENG
1
;
Yilin MA
Author Information
1. 传染病重症诊治全国重点实验室 国家感染性疾病临床医学研究中心 浙江大学医学院附属第一医院感染病科，杭州 310003
- Keywords:
COVID-19;
Azvudine;
Deuremidevir;
Hydrobromide;
Simnotrelvir/Ritonavir;
Leritrelvir;
Antiviral drug
- From:
Chinese Journal of Clinical Infectious Diseases
2023;16(5):393-400
- CountryChina
- Language:Chinese
-
Abstract:
The National Medical Products Administration has approved 6 small molecule drugs against novel coronavirus for marketing since 2022, of which 2 are imported drugs: Paxlovid (Nirmatrelvir/Ritonavir) of Pfizer and Molnupiravir of Merck; 4 are domestic products: Azvudine of Real, Deuremidevir Hydrobromide (VV116) of Junshi Biologics, Simnotrelvir/Ritonavir of Simcere pharmaceutical and Leritrelvir of Zhongsheng pharmaceutical. The overall mechanism of action if these drugs is inhibiting protease and RNA-dependent RNA polymerase to eliminate novel coronavirus. If applied early, the clinical symptoms can be effectively controlled and complications can be reduced. In this article, the resent progress of 6 newly approved anti-novel coronavirus small molecular drugs in China is reviewed for reference of clinical application.
